The company reported solid second-quarter 2019 operating results, but significantly reduced production expansion plans.
The company confirmed that it has been approached for a takeover, but nothing is guaranteed.
These two businesses could receive a big boost this month if certain events fall in their favor.
The solar-hardware stock has now given up all gains since second-quarter 2019 operating results were announced.
The company is reportedly considering bankruptcy to cope with its financial exposure in the opioid crisis.
The pharma company could earn its first drug approval in January 2020. What happens after that?
The DNA sequencing pioneer promised a $1,000 human genome by early 2019. The price isn't so important, but the technology upgrades will prove critical.
Investors need ongoing clinical trials to deliver -- and for the business to rein in expenses.
The business is profitable, investing in the future, and pays a healthy annual dividend yielding 5%. Shares look like a bargain, too.
These growth stocks are trading at reasonable prices -- exactly the kind of investment the investing guru sought.
The pharma company has wowed investors with solid clinical data multiple times this year.
The business might yet prove to be a less risky play on the rise of cannabis, but it has plenty left to prove to investors.
Your money can buy more shares of these promising companies thanks to an affordable stock price.
The generic drug manufacturer announced fiscal 2019 results and inked an important supply deal.
These businesses offer the potential for above-average returns that could receive a huge helping hand from the power of compound interest.
The precious metal has been rising in price as global economic headwinds mount.
The company is flush with cash and wields a promising therapeutic pipeline. Is its recent tumble a buying opportunity?
The bad news keeps piling up.
China has decided that American oil exports, a relative strength in recent years, are fair game in the trade war.
The dog days of summer are finally behind us (on the calendar, anyway), but these three stocks offer sizzling growth potential.